Dry eye study seeks better ways to measure disease

NCT ID NCT07025811

Completed Knowledge-focused Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 28, 2026 · Updated 3 times

Summary

This study tracks 378 people with moderate to severe dry eye disease and healthy volunteers to see how signs, symptoms, and biomarkers change after treatment with either Vevye or Xiidra eye drops. The goal is to find better ways to measure the disease and its response to therapy. Participants will receive standard anti-inflammatory eye drops and be monitored over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cyclosporine ophthalmic solution (Vevye) and lifitegrast ophthalmic solution (Xiidra)
What this could lead to: If successful, this study could help doctors better understand and measure dry eye disease, leading to more personalized treatments.
What could go wrong: This is an observational study focused on biomarkers, not a treatment trial. It may not lead to new therapies, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRY EYE DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dry eye syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRY EYE DISEASE

Contacts and locations

Locations

Advancing Vision Research, LLC

Goodlettsville, Tennessee, 37072, United States
Andover Eye Associates

Andover, Massachusetts, 01810, United States
Butchertown Clinical Trials

Louisville, Kentucky, 40206, United States
CORE Inc.

Shelby, North Carolina, 28150, United States
Eye Research Foundation

Newport Beach, California, 92663, United States
Oculus Research

Garner, North Carolina, 27529, United States
Piedmont Eye Center

Lynchburg, Virginia, 24502, United States
Total Eyecare, P.A.

Memphis, Tennessee, 38119, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.